Unanticipated 30-day readmission following rectosigmoid resection at the time of cytoreductive surgery in patients with advanced stage ovarian cancer

References

• AlHilli M, Langstraat C, Tran C, Martin J, Weaver A, McGree M, et al. 2015. Risk factors and indications for 30-day readmission after primary surgery for epithelial ovarian cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society 25:193–202.
   PubMed Web of Science ®Google Scholar
• Barber EL, Doll KM, Gehrig PA. 2017. Hospital readmission after ovarian cancer surgery: are we measuring surgical quality? Gynecologic Oncology 146:368–372.
   PubMed Web of Science ®Google Scholar
• Berek JS, Hacker NF, Lagasse LD. 1984. Rectosigmoid colectomy and reanastomosis to facilitate resection of primary and recurrent gynecologic cancer. Obstetrics and Gynecology 64:715–720.
   PubMed Web of Science ®Google Scholar
• Berwick DM, Hackbarth AD. 2012. Eliminating waste in US health care. JAMA 307:1513–1516.
   PubMed Web of Science ®Google Scholar
• Bhagwandin SB, Naffouje S, Salti G. 2015. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge. Journal of Surgical Oncology 111:324–327.
   PubMed Web of Science ®Google Scholar
• Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. 2002. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Journal of Clinical Oncology 20:1248–1259.
   PubMed Web of Science ®Google Scholar
• Ceppa EP, Pitt HA, Nakeeb A, Schmidt CM, Zyromski NJ, House MG, et al. 2015. Reducing readmissions after pancreatectomy: limiting complications and coordinating the care continuum. Journal of the American College of Surgeons 221:708–716.
   PubMed Web of Science ®Google Scholar
• Charoenkwan K, Matovinovic E. 2014. Early versus delayed oral fluids and food for reducing complications after major abdominal gynaecologic surgery. Cochrane Database Systemic Review 17:CD004508.
   Google Scholar
• Chough I, Zaghiyan K, Ovsepyan G, Fleshner P. 2018. Practice changes in postoperative feeding after elective colorectal surgery: from prospective randomized study to everyday practice. American Surgeon 84:1675–1678.
   PubMed Web of Science ®Google Scholar
• Clark RM, Growdon WB, Wiechert A, Boruta D, Del Carmen M, Goodman AK, et al. 2013. Patient, treatment and discharge factors associated with hospital readmission within 30 days after surgical cytoreduction for epithelial ovarian carcinoma. Gynecologic Oncology 130:407–410.
   PubMed Web of Science ®Google Scholar
• Cripe J, Tseng J, Eskander R, Fader AN, Tanner E, Bristow R. 2015. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent ovarian carcinoma: analysis of 30-day morbidity and mortality. Annals of Surgical Oncology 22:655–661.
   PubMed Web of Science ®Google Scholar
• Eskander RN, Chang J, Ziogas A, Anton-Culver H, Bristow RE. 2014. Evaluation of 30-day hospital readmission after surgery for advanced-stage ovarian cancer in a medicare population. Journal of Clinical Oncology 32:4113–4119.
   PubMed Web of Science ®Google Scholar
• Fauci JM, Schneider KE, Frederick PJ, Wilding G, Consiglio J, Sutton AL, et al. 2011. Assessment of risk factors for 30-day hospital readmission after surgical cytoreduction in epithelial ovarian carcinoma. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 21:806–810.
   PubMed Web of Science ®Google Scholar
• Gerardi MA, Santillan A, Meisner B, Zahurak ML, Diaz Montes TP, Giuntoli RL, Bristow RE. 2008. A clinical pathway for patients undergoing primary cytoreductive surgery with rectosigmoid colectomy for advanced ovarian and primary peritoneal cancers. Gynecologic Oncology 108:282–286.
   PubMed Web of Science ®Google Scholar
• Jencks SF, Williams MV, Coleman EA. 2009. Rehospitalizations among patients in the Medicare fee-for-service program. New England Journal of Medicine 360:1418–1428.
   PubMed Web of Science ®Google Scholar
• Kent TS, Sachs TE, Callery MP, Vollmer CM. 2011. Readmission after major pancreatic resection: a necessary evil? Journal of the American College of Surgeons 213:515–523.
   PubMed Web of Science ®Google Scholar
• Nelson G, Dowdy SC, Lasala J, Mena G, Bakkum-Gamez J, Meyer LA, et al. 2017. Enhanced recovery after surgery (ERAS®) in gynecologic oncology – practical considerations for program development. Gynecologic Oncology 147:617–620.
   PubMed Web of Science ®Google Scholar
• Peiretti M, Bristow RE, Zapardiel I, Gerardi M, Zanagnolo V, Biffi R, et al. 2012. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic Oncology 126:220–223.
   PubMed Web of Science ®Google Scholar
• Rachidi S, Li H, Wallace K, Li Z, Balch C, Lautenschlaeger T. 2020. Preoperative platelet counts and postoperative outcomes in cancer surgery: a multicenter, retrospective cohort study. Platelets 31:79–79.
   PubMed Web of Science ®Google Scholar
• Reissman P, Teoh TA, Cohen SM, Weiss EG, Nogueras JJ, Wexner SD. 1995. Is early oral feeding safe after elective colorectal surgery? A prospective randomized trial. Annals of Surgery 222:73–77.
   PubMed Web of Science ®Google Scholar
• Shau H, Roth MD, Golub SH. 1993. Regulation of natural killer function by nonlymphoid cells. Natural Immunity 12:235–249.
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Jemal A. 2019. Cancer statistics, 2019. CA: A Cancer Journal for Clinicians 69:7–34.
   PubMed Web of Science ®Google Scholar
• Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE. 1998. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clinical Science 94:395–404.
   PubMed Web of Science ®Google Scholar
• Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. 2016. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology 34:3460–3473.
   PubMed Web of Science ®Google Scholar